Skip NavigationSkip to Content
Return Return to Search Results

Discovery of new pyridoacridine alkaloids from Lissoclinum cf. badium that inhibit the ubiquitin ligase activity of Hdm2 and stabilize p53

  1. Author:
    Clement, J. A.
    Kitagaki, J.
    Yang, Y.
    Saucedo, C. J.
    O'Keefe, B. R.
    Weissman, A. M.
    Mckee, T. C.
    McMahon, J. B.

  2. Author Address

    Kitagaki, Jirouta, Yang, Yili, Weissman, Allan M.] NCI, Lab Prot Dynam & Signaling, Ctr Canc Res, NIH, Frederick, MD 21702 USA. [Clement, Jason A.; O'Keefe, Barry R.; Mckee, Tawnya C.; McMahon, James B.] NCI, Mol Targets Dev Program, Ctr Canc Res, NIH, Frederick, MD 21702 USA. [Saucedo, Carrie J.] NCI, SAIC Frederick Inc, NIH, Frederick, MD 21702 USA.
    1. Year: 2008
  2. Journal: Bioorganic & Medicinal Chemistry
    1. 16
    2. 23
    3. Pages: 10022-10028
  4. Type of Article: Article
  1. Abstract:

    Compounds that stabilize p53 could suppress tumors providing a additional tool to fight cancer. Mdm2, and the human ortholog, Hdm2 serve as ubiquitin E3 ligases and target p53 for ubiquitylation and degradation. Inhibition of Hdm2 stabilizes p53, inhibits cell proliferation and induces apoptosis. Using HTS to discover inhibitors, we identified three new alkaloids, isolissoclinotoxin B, diplamine B, and lissoclinidine B from Lissoclinum cf. badium. Lissoclinidine B inhibited ubiquitylation and degradation of p53, and selectively killed transformed cells harboring wild-type p53, suggesting this compound could be used to develop new treatments. (c) 2008 Elsevier Ltd. All rights reserved.

    See More

  1. Keywords:

External Sources

  1. PMID: 18977148

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel